ACUR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACUR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Acura Pharmaceuticals's Sloan Ratio for the quarter that ended in Dec. 2021 was 0.00%.
As of Dec. 2021, Acura Pharmaceuticals has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
The historical data trend for Acura Pharmaceuticals's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acura Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Sloan Ratio % | Get a 7-Day Free Trial | -32.17 | - | - | - | - |
Acura Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | |
Sloan Ratio % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Acura Pharmaceuticals's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Acura Pharmaceuticals's Sloan Ratio for the fiscal year that ended in Dec. 2021 is calculated as
Sloan Ratio | = | (Net Income (A: Dec. 2021 ) | - | Cash Flow from Operations (A: Dec. 2021 ) |
- | Cash Flow from Investing (A: Dec. 2021 )) | / | Total Assets (A: Dec. 2021 ) | |
= | (-0.879 | - | -0.742 | |
- | 0) | / | 0.86 | |
= | -15.93% |
Acura Pharmaceuticals's Sloan Ratio for the quarter that ended in Dec. 2021 is calculated as
Sloan Ratio | = | (Net Income (TTM) | - | Cash Flow from Operations (TTM)) |
- | Cash Flow from Investing (TTM)) | / | Total Assets (Q: Dec. 2021 ) | |
= | (-0.879 | - | -0.742 | |
- | 0) | / | 0.86 | |
= | -15.93% |
Acura Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Dec. 2021 was -0.259 (Mar. 2021 ) + -0.387 (Jun. 2021 ) + -0.262 (Sep. 2021 ) + 0.029 (Dec. 2021 ) = $-0.88 Mil. Acura Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2021 was -0.313 (Mar. 2021 ) + -0.194 (Jun. 2021 ) + 0.191 (Sep. 2021 ) + -0.426 (Dec. 2021 ) = $-0.74 Mil. Acura Pharmaceuticals's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2021 was 0 (Mar. 2021 ) + 0 (Jun. 2021 ) + 0 (Sep. 2021 ) + 0 (Dec. 2021 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acura Pharmaceuticals (OTCPK:ACUR) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
According to How to Beat the Market with the Sloan Ratio:
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2021, Acura Pharmaceuticals has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Thank you for viewing the detailed overview of Acura Pharmaceuticals's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bruce F Wesson | director | 1827 PACIFIC ST BROOKLYN NY 11233 |
William G Skelly | director | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 |
George K Ross | director | 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596 |
James F Emigh | officer: VP, Corporate Development | |
Immanuel Thangaraj | director | 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380 |
Robert A Seiser | officer: VP, Treasurer & Controller | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067 |
Robert B Jones | officer: President & CEO | C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067 |
Albert W Brzeczko | officer: VP Pharmaceutical Sciences APT | C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067 |
Peter A Clemens | officer: Senior VP & CFO | C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233 |
Abuse Deterrent Pharma, Llc | 10 percent owner | 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202 |
Claudius Llc | 10 percent owner | C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
John Schutte | 10 percent owner | 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233 |
Galen Partners Iii L P | 10 percent owner | 610 FIFTH AVE 5TH FL NEW YORK NY 10020 |
Galen Management, Llc | 10 percent owner | 680 WASHINGTON BLVD, STAMFORD CT 06901 |
Galen Employee Fund Iii Lp | 10 percent owner | 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
From GuruFocus
By gurufocus 10qk • 03-01-2011
By Marketwired Marketwired • 03-31-2020
By Marketwired Marketwired • 05-17-2021
By Marketwired Marketwired • 10-01-2019
By Marketwired Marketwired • 10-10-2018
By Marketwired Marketwired • 09-09-2019
By gurufocus 10qk • 07-29-2010
By Marketwired Marketwired • 10-29-2020
By Marketwired Marketwired • 06-14-2021
By Marketwired Marketwired • 02-11-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.